🇺🇸 FDA
Patent

US 8501704

Immunosuppression compound and treatment method

granted A61PA61P3/00A61P37/00

Quick answer

US patent 8501704 (Immunosuppression compound and treatment method) held by Sarepta Therapeutics, Inc. expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P3/00, A61P37/00, A61P37/06